Summary of results
| sAAA− | sAAA+ | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Group | N | PASI | TNFα (pg/mL) | N | PASI | TNFα (pg/mL) | False-positive/spurious | sADL CVb (mean fold change) | sAAA CVb (mean fold change) |
| I (n=20) | 7 | – | – | 13 | – | – | 0 | 50 | 23 |
| II (n=30) | 34 | 26 | |||||||
| Trecruitment | 14 | 1.1 (0–14) | 0.12 (0–1.42) | 6 | 4.0 (0.2–8.0) | 0.04 (0–0.54) | 2 | ||
| T12 | 16 | 0.2 (0–3.2) | 0.14 (0–1.3) | 4 | 0.8 (0.2–1.2) | 0 (0–0.14) | 0 | ||
| III (n=30) | 48 | 25 | |||||||
| T0 | 25 | 12 (4–22) | 0 (0–6.61) | 5 | 11.2 (2.5–21) | 0.63 (0–6.73) | 5 | ||
| T1 | 25 | 4.5 (0.8–9.5) | 0 (0–0.18) | 5 | 4.5 (0–17.5) | 0 (0–0.91) | 5 | ||
| T3 | 28 | 0.65 (0–4.5) | 0 (0–0.60) | 2 | 0.7 (0–13) | 0 (0–0.56) | 2 | ||
| T6 | 25 | 0 (0–4) | 0.09 (0–1.78) | 5 | 1.5 (0–5) | 0 (0–1.86) | – | ||
| IV (n=15) | 8 | – | – | 7 | – | – | 7 | – | – |
| V (n=15) | 10 | – | – | 5 | – | – | 5 | – | – |
Values are expressed as median (range), where applicable, or as pure numbers.
Specific features of the study cohorts are detailed in the text.
CVb, interassay variability (expressed as mean fold change); group I, ex-ADL; group II, on-ADL; group III, naïve patients; group IV, on-BIO; group V, healthy controls; PASI, Psoriasis Area Severity Index; sAAA−, patients negative for serum anti-adalimumab antibodies; sAAA+, patients positive for serum anti-Adalimumab antibodies; sAAA, serum titre of anti-adalimumab antibodies (AU/mL); sADL serum adalimumab concentrations (μg/mL); TNFα, tumour necrosis factor α.